Latest Information Update: 30 Nov 2015
At a glance
- Originator Health Ever Bio-Tech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 04 Nov 2015 Health Ever Biotech initiates enrolment in a phase II trial for Prostate cancer (Prevention) in Taiwan
- 01 Oct 2014 Phase-II clinical trials in Prostate cancer (Prevention) in Taiwan (PO) (NCT02042807)